SCHEMBL173771

SCHEMBL173771

C[N+](C)(CCCNCl)CCCS(=O)(=O)O

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BBOX1 O75936 4/20 0.36
APP P05067 1/20 0.34
EPHX2 P34913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL918271 0.84 BBOX1 (0.46) BBOX1APP
SCHEMBL18270969 0.83 BBOX1 (0.37) BBOX1APPEPHX2
SCHEMBL18270968 0.81 BBOX1 (0.36) BBOX1APPEPHX2
SCHEMBL368076 0.81 BBOX1 (0.58) BBOX1
SCHEMBL21024442 0.80 CBLB (0.42) BBOX1APPEPHX2
SCHEMBL22006989 0.80 BBOX1 (0.43) BBOX1APP
SCHEMBL3381684 0.80
SCHEMBL13978757 0.79 BBOX1 (0.37) BBOX1APPEPHX2
SCHEMBL12210469 0.79 KDM4E (0.50) BBOX1EPHX2
SCHEMBL19170095 0.79 BBOX1 (0.34) BBOX1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7236236-B2 Methods for detecting malaria parasites and reagent kits therefor SYSMEX CORPORATION (JP) 2007-06-26 US claimed
WO-2005039381-A2 COMPOSITIONS AND PROCESSES FOR ANALYSIS OF PHARMACOLOGIC AGENTS IN BIOLOGICAL SAMPLES DRUG RISK SOLUTIONS, L.L.C. (US) 2005-05-06 WO claimed
US-20050042675-A1 Solution for preparing stool specimens for diagnostic purposes CONNEX GESELLSCHAFT ZUR OPTIMIERUNG VON FORSCHUNG UND ENTWICKLUNG MBH (DE) 2005-02-24 US claimed
US-20050037386-A1 Composition and processes for analysis of pharmacologic agents in biological samples DRUG RISK SOLUTIONS, L.L.C. 2005-02-17 US claimed
EP-0433225-B1 Process for the production of biologically active protein (e.g. TGF) NOVARTIS AG (CH) 1999-04-07 EP claimed
US-5389549-A Method for classifying leukocytes and a reagent used therefor TOA MEDICAL ELECTRONICS CO., LTD. (JP) 1995-02-14 US claimed
US-11629154-B2 Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity SHIONOGI & CO., LTD. (JP) 2023-04-18 US disclosed
EP-3784674-B1 TETRAHYDROPYRANOOXAZINE DERIVATIVES HAVING SELECTIVE BACE1 INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2023-02-22 EP disclosed
CN-112708621-B Sequentially-lighted multicolor DNA tetrahedral nanoprobe SLMN and preparation method and application thereof 山东大学 2022-09-02 CN disclosed
CN-113201579-B Telomerase detection system, telomerase detection method and telomerase detection kit for targeting tumors 山东大学 2022-08-23 CN disclosed
CN-113382981-A Disulfide compounds 尼姆生物科技有限公司 2021-09-10 CN disclosed
US-20210238194-A1 TETRAHYDROPYRANOOXAZINE DERIVATIVES HAVING SELECTIVE BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2021-08-05 US disclosed
CN-113201579-A Telomerase detection system, telomerase detection method and telomerase detection kit for targeting tumors 山东大学 2021-08-03 CN disclosed
US-5389549-A Method for classifying leukocytes and a reagent used therefor TOA MEDICAL ELECTRONICS CO., LTD. (JP) 1995-02-14 US disclosed
EP-0617281-A2 A reagent for measuring immature leukocytes TOA MEDICAL ELECTRONICS CO., LTD. (JP) 1994-09-28 EP disclosed
US-5330902-A DNA encoding a helical polypeptide attached to a gene endcoding a protein spontaneously forms inclusion bodies; purification and cleavage to separate amphilic helix from product CREATIVE BIOMOLECULES, INC. (US) 1994-07-19 US disclosed
US-5302526-A Genetic engineering CREATIVE BIOMOLECULES, INC. (US) 1994-04-12 US disclosed
US-5215896-A Pendant polypeptide with amphiphilic helical structure CREATIVE BIOMOLECULES, INC. (US) 1993-06-01 US disclosed
EP-0503297-A1 GLIA activating factor and its production TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1992-09-16 EP disclosed
US-5011910-A Heptapeptides having fluorogenic and quenching groups as substrates for protease; colorimetric analysis, efficiency WASHINGTON UNIVERSITY (US) 1991-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11629154-B2 Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity BACE1, APP, BACE2 BBOX1 79/4885APP 2/4885EPHX2 1945/4885
US-20210238194-A1 TETRAHYDROPYRANOOXAZINE DERIVATIVES HAVING SELECTIVE BACE1 INHIBITORY ACTIVITY BACE1, APP, BACE2 BBOX1 79/4885APP 2/4885EPHX2 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.